Synthetic pentadecapeptide ('body protection compound')
Lab-made 15-amino-acid peptide studied mainly in animals for healing tendon, muscle, gut and other tissue.
| Class / type | Synthetic pentadecapeptide ('body protection compound') |
|---|---|
| Category | Healing, Recovery & Immune |
| Status (Jul 2026) | Research use only |
BPC-157 ('body protection compound') is a lab-made peptide derived from a fragment of a protein found in human gastric juice. It is one of the most talked-about 'healing' peptides in the fitness and recovery communities.
The enthusiasm rests almost entirely on animal studies and anecdote - there are essentially no controlled human trials. It is not FDA-approved, and its US compounding status is actively changing in 2026 (see legal status).
In animal models, BPC-157 appears to modulate blood-vessel growth (angiogenesis) via the VEGFR2 and nitric-oxide pathways, upregulate growth-hormone receptors in fibroblasts, and engage FAK/ERK signaling. The net effect in these studies is faster healing of tendon, muscle, gut and other tissues, plus anti-inflammatory and cytoprotective actions.
Proponents describe the angiogenic effect as 'modulatory' - normalizing vessel growth where needed - rather than a blanket signal to grow vessels everywhere, though this distinction is not settled in humans.
The evidence base is roughly three dozen animal studies and very little human data. Rodent work consistently shows tendon-to-bone healing, gut protection (ulcer and colitis models), and reduced inflammation. Standard genotoxicity tests have not flagged DNA damage.
What is missing is controlled human efficacy and long-term safety data - so benefits reported by users remain anecdotal rather than proven.
Widely reported (anecdotally) to help stubborn tendon and joint injuries and gut issues that had not responded to conventional care, and it is often stacked with TB-500.
Strong, reproducible preclinical healing signals give a plausible biological rationale, even if human proof is lacking.
There is no published long-term human safety data and essentially no controlled human trials, so the true risk profile is unknown.
The central theoretical concern is that the same pro-healing actions - growing new blood vessels and prompting cells to multiply and migrate - are processes tumors also rely on to grow and spread. In principle this could feed a cancer someone does not yet know they have. It is unproven either way, but it matters most for anyone with a personal or family history of cancer. Mild reported effects include nausea and headache, and gray-market purity is a real concern.
BPC-157 is sold 'for research use only'. There is no FDA-sanctioned human dose. Because product quality varies widely on the gray market, purity and sterility are genuine unknowns.
Faster recovery from chronic tendon/joint injuries that didn't respond to conventional care; gut relief.
NOT FDA-approved. Removed from Category 2 (Apr 2026); scheduled for FDA PCAC review Jul 23, 2026 - FDA's PROPOSED position is NOT to add it to the 503A list. Status in flux; verify.